The Development, Uses and Future of Gerovital H3

Introduction  |   From the Past to the Present  |   The Nature of Gerovital H3
Research and Speculation on Possible Benefits  |   Some Additional Clinical Considerations
An Intangible Field of Resistance  |   The Future of Gerovital H3  |   Footnotes  |   Bibliography

FOOTNOTES

1 Godin, Jerome, GH3 Discovery (Miami: J.S. Publishers, 1979), pp.9-10.
2 Ibid., p. 10
3 Bailey, Herbert, GH3: Will It Keep You Young Longer? (New York, Bantam Books, 1977), pp.3-7.
4 Aslan, Ana, Gerovital H3 (Vancouver, B.C.: Phoenix Creation Ltd., 1982) pp. 24-25
5 Bailey, pp. 5-6.
6 Journal of the American Med. Assn., New Drugs and Developments in Therapeutics, “Procaine-At Last Its Song Is Ended” (Council on Drugs [now defunct]) 180:965,1963.
7 Abrams, A.; Tobin, S.; Gordon, P.; Pechtel, C. and Hilkevitch, A. “The Effects of a European Procaine Preparation in an Aged Population (I).” J. Geron., 20:139, 1965.
8 Bailey, p.8
9 Ibid., p.108.
10 Godin, p.16.
11 Ibid., p.9.
12 Bailey, p.109.
13 Godin, p.17.
14 Bailey, p.108.
15 Ibid.
16 Zung, W.W.K.; Gianturco, D.; Pfeiffer, E.; Wang, H.; Whanger, A.; Bridge, T. and Potkin, S. “Pharmacology of Depression in the Aged: Evaluation of Gerovital H3 as an Antidepressant Drug.” Psychosomatics, 15 (1974): 127-131.
17 Aslan, A. and Ciuca, A. “Results of Some Practical Researches in the Field of Social Gerontoprophylaxis.” Paper presented at the International Symposium of Gerontology, Bucharest, Romania, June 26-7, 1972. (Re printed in Bailey, op. cit., pp. 130-133.)
18 Cohen, S. “Clinical Experiences with Gerovital.” Presented at a State-of- the-Art Workshop on Procaine and Related Geropharmacologic Agents, Feb. 14, 1975, V. A. Central Ofc., Washington, D.C. (Reprinted in Bailey, op. cit., pp. 130-133.)
19 Aslan, 1972.
20 Aslan, 1982, p. 12.
21 Gordon, P.; Fudema, J. and Abrams, A. “The Effects of a European Procaine Preparation in an Aged Population (II).” J. Geront., 20:144, 1965.
22 Aslan, 1972.
23 Godin, p. 22.
24 Aslan, 1982, p. 51
25 Godin, p.22.
26 Kohler, U. and Mampel, E.: Fragen uber Novokain Behandlung. Munchen Med. Wschr. 100/15, p.597,1958.
27 Robinson, D.S.; Davis, J.M.; Nies, A.; Colburn, R.W.; Davis, J.N.; Bourne, H.R.; Bunney, W.E.: Shaw, D.M. and Coppen, A.J. “Ageing, Monoamines and Monoamine Oxidase Levels.” Lancet, #7745:290,1972.
28 Bucci, L. “Procaine: A Monoamine Oxidase Inhibitor in Schizophrenia”. Diseases of the Nervous System: A Practical Journal on Psychiatry and Neurology. Physicians Post-Graduate Press, lnc., 34 (1973)389-391.
29 MacFarlane, M.D. “Procaine (Gerovital H3) Therapy: Mechanisms of Inhibition of Monoamine Oxidase”. Journal of the American Geriatrics Society, 22 (1974):365-371.
30 MacFarlane, M.D. “Procaine HCL (Gerovital H3): A Weak, Reversible, Fully Competitive Inhibitor of Monoamine Oxidase.” Federation Proceedings 34 (1975):108-1 10.
31 Hrachovec, J. “Inhibitory Effect of Gerovital H3 on Monoamine Oxidase in Rat Brain, Liver and Heart.” The Physiologist 15 (1972).
32 Bailey, p.86.
33 Aslan, A. and Parhon, C.l. Novacain, Eutrophic and Rejuvenating Factor in the Preventive and Curative Treatment of Old Age. Romanian Academy, 1954.
34 Untea, G.; Vionea, R. and Pirvulescu, I. “Considerations Regarding the Usage of Gerovital H3 During Andropause for Disturbances of Sexual Dynamics”. Giorn. Gerontology, 20, 1, pp. 62-69,1972.
35 Bailey, p.80.
36 Officer, J.E. “Procaine-HCL Growth Enhancing Effects on Aged Mouse Embryo Fibroplasts Cultured In Vitro.” Presented at the 26th annual meeting of the Gerontological Society, Miami, November, 1973. (Reprinted in Bailey, op. cit., pp.245-249.)
37 Aslan, A. “The Therapeutics of Old Age. The Action of Procaine-Clinical and Experimental Conclusions.” Medical and Clinical Aspects of Ageing (New York: Columbia Univ. Press, 1962), pp.272-292.
38 Cohen, S. and Ditman, K. “Gerovital H3 in the Treatment of the Depressed Aging Patient.” Psychosoma tics 14 (1 974):1 5-19.
39 Aslan, 1982, p.25.
40 Ibid., p.22.
41 Ibid., p.25.
42 Bucci, L. and Saunders, J.C. “A Psychopharmacological Evaluation of 2-Diethylamino-ethyl-p-aminobenzoate (Procaine).” Journal of Neuropsych. 1 (1959):276-281.
43 Bucci, 1973.
44 Bailey, p.107.
45 Bucci, L. “The MAO Inhibitory Activity of Procaine.” Presented at the International Symposium of Gerontology, Bucharest, Romania, June 26-7, 1972. (Reprinted in Bailey, op. cit., pp. 162-164.)
46 Godin, p. 17.
47 Aslan, 1982, p. 25.
48 Godin, p. 15.
49 Bailey, p. PP. 57-58
50 Godin, p. 15.
51 Bailey, p. 103.
52 Bucci and Saunders, p. 279.
53 Aslan and Ciuca, 1972.
54 Untea, G. and Bercu, G. “Considerations on the Influence Exerted by the Treatment of Gerovital H3 Tablets on the Work Capacity of Active Persons Past the Age of 45.” Giorn. Geront. 17 (1969):795-799.
55 Aslan, A.: Uberblick uber den heutigen Stand der Novokainbehandlung der Alternserscheinungen. Therapiewoche, 15/3 (1965), pp. 143-148.
56 Smigel, J.; Piller, J.et al. “H3 (procaine hydrochloride) Therapy in Ageing Institutionalized Patients: An Interim Report.” J. American Gero. Society, 8 (1960): 785-795.
57 MacFarlane, M.D. and Desbris, H. “Procaine (Gerovital H3) Therapy: Mechanisms of Inhibition of Monaomine Oxidase.” J American Ger. Soc. (1974): 365-371.
58 Depression Today, part 3. CME Communications, Inc., N.Y., N.Y., 1978.
59 Zung, et al., 1974, pp. 130-131.
60 Bailey, pp. 110-112.
61 Aslan, 1982, p. 54.
62 Godin, p. 25.
63 Aslan, 1982, p.54.
64 Siggelkov, H.: Zur Behandlung des apoplektischen Syndroms. Z. Alternsferschung 20/3-4 (1967):239.
65 Bailey, 82-83.
66 Aslan, 1982, p.25.
67 Baker, R.; Powars, D. and Haywood, L. “Restoration of the Deformability of ‘Irreversibly’ Sickled Cells by Procaine Hydrochloride.” Biochem. and Biophys. Research Communications 59 (1974): 548-556.
68 David, C. and Popovici, M.: Un cas de diabete resistant a l’insuline. Communic., USSM, Gerontoligie, Bucharest, Nov. 1959.
69 Bucci, 1972.
70 Bailey, p.107.
71 Godin, pp. 22-23.
72 Ibid., p. 29.
73 Aslan, 1982, p. 25
74 Ibid, p. 15.
75 Ibid., p. 54.
76 Bailey, pp. 87-98.
77 Berger, P.: Les effects du traitement chronique sur la senescence du rat blanc. Premiers resultats. Path. et Biol. 8 (1960):1163-1166.
78 Hochschild, R. “Effects of DMAE on Depression, on In Vitro Cell Survival and on Animal Life Span.” Presented at State-of-the-Art Workshop on Procaine and Related Geropharmacologic Agents. 14 Feb., 1975, V. A. Central Ofc., Washington, D.C. (Reprinted in Bailey, op.cit., pp. 289-291.)
79 Aslan, 1982, p.33.
80 Aslan, A. “Theoretical and Practical Aspects of Chemotherapeutic Tech niques In The Retardation of the Aging Process.” Paper presented at the Symposium on Theoretical Aspects of Aging, Miami, Feb., 1974. (Re printed in Bailey, op. cit., pp. 258-267.)
81 Wagner, B.M. “Possible Site of Action of Gerovital H3 In the Central Nervous System.” Paper presented at the 26th Annual Scientific Meeting of the Gerontological Society, Nov., 1973.
82 Pfeiffer, C.C.; Goldstein, L.’ Murphree, H. and Nichols, R. “A Critical Survey of Possible Biochemical Stimulants.” U.S. Public Health Service Publication 1836 (1968).
83 Aslan, 1982, pp. 34-36.
84 Bucci and Saunders, pp. 276-277.
85Goodman, L.A. and Gilman, A. The Pharmacological Basis of Therapeu tics (2nd ed.), The Macmillan Co., New York, 1955.
86 Aslan, 1974.
87 Bailey, pp. 109-110.
88 Aslan, 1982, p. 62.
89 Ibid., p. 14
90 Preventative Health News, Jan. 1982, p. 6.
91 21 United States Code, 350
92 Hecht, Anna, “Time Marches on Despite Gerovital.” FDA Consumer, Vol. 14, March, 1980. pp. 16-20.
93 Bailey, p. 104.